These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19452773)

  • 1. [Adverse effect of valaciclovir in disturbed kidney function].
    van Berlo-van de Laar IR; Goet ER; Helldén A; Sluiter HE
    Ned Tijdschr Geneeskd; 2009 Apr; 153(15):706-9. PubMed ID: 19452773
    [No Abstract]   [Full Text] [Related]  

  • 2. [Risk of CNS adverse effects of aciclovir and valaciclovir. Watch the renal function in treatment of herpes simplex and herpes zoster].
    Helldén A; Bergman U; Dwyer R; Medin C; Molanaei H; Ståhle L; Thylén P; Odar-Cederlöf I
    Lakartidningen; 2007 Jun 13-26; 104(24-25):1916-20. PubMed ID: 17674672
    [No Abstract]   [Full Text] [Related]  

  • 3. Valacyclovir neurotoxicity can be effectively managed by hemodialysis.
    Kambhampati G; Pakkivenkata U; Kazory A
    Eur J Neurol; 2011 Mar; 18(3):e33. PubMed ID: 21087359
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neurotoxicity after the first dose of oral administration of valaciclovir in a female hemodialyzed patient].
    Saurina A; Ramírez de Arellano M; de las Cuevas X
    Nefrologia; 2002; 22(1):83-4. PubMed ID: 11987691
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of orally administered valacyclovir in experimentally EHV1-infected ponies.
    Garré B; Gryspeerdt A; Croubels S; De Backer P; Nauwynck H
    Vet Microbiol; 2009 Mar; 135(3-4):214-21. PubMed ID: 18986780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Valaciclovir].
    Taéron C
    Rev Infirm; 2007 Dec; (136):47-8. PubMed ID: 18257501
    [No Abstract]   [Full Text] [Related]  

  • 7. Valacyclovir-induced seizures in end-stage renal disease.
    Rivkin AM
    Ann Pharmacother; 2003 Dec; 37(12):1913. PubMed ID: 14632595
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of valacyclovir in the adult horse.
    Maxwell LK; Bentz BG; Bourne DW; Erkert RS
    J Vet Pharmacol Ther; 2008 Aug; 31(4):312-20. PubMed ID: 18638291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of valaciclovir.
    MacDougall C; Guglielmo BJ
    J Antimicrob Chemother; 2004 Jun; 53(6):899-901. PubMed ID: 15140857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oliguric acute renal failure following oral valacyclovir therapy.
    Sugimoto T; Yasuda M; Sakaguchi M; Koyama T; Uzu T; Kashiwagi A; Isshiki K; Kanasaki M
    QJM; 2008 Feb; 101(2):164-6. PubMed ID: 18180255
    [No Abstract]   [Full Text] [Related]  

  • 11. Infection fighters. High-dose Valtrex for oral hairy leukoplakia.
    TreatmentUpdate; 2003; 15(7):6-7. PubMed ID: 17216869
    [No Abstract]   [Full Text] [Related]  

  • 12. [Valaciclovir-related neuro- and nephro-toxicity in two geriatric patients].
    Catalano C; Conforto L
    G Ital Nefrol; 2005; 22 Suppl 31():S132-4. PubMed ID: 15786387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.
    Helldén A; Lycke J; Vander T; Svensson JO; Odar-Cederlöf I; Ståhle L
    J Antimicrob Chemother; 2006 May; 57(5):945-9. PubMed ID: 16540518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allergic drug eruption secondary to intravenous acyclovir.
    Schuster J; Fabri M; Eming S; Hunzelmann N
    Acta Derm Venereol; 2008; 88(2):196-8. PubMed ID: 18311465
    [No Abstract]   [Full Text] [Related]  

  • 15. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of valaciclovir polybutylcyanoacrylate nanoparticles].
    He Q; Zhang Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1998 Sep; 29(3):272-4. PubMed ID: 10684090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immediate allergy from valacyclovir.
    Ebo DG; Bridts CH; De Clerck LS; Stevens WJ
    Allergy; 2008 Jul; 63(7):941-2. PubMed ID: 18588563
    [No Abstract]   [Full Text] [Related]  

  • 18. Symmetrical drug-related intertriginous and flexural exanthema caused by valacyclovir.
    Daito J; Hanada K; Katoh N; Katoh S; Sakamoto K; Asai J; Takenaka H; Kishimoto S
    Dermatology; 2009; 218(1):60-2. PubMed ID: 18974630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurring meningitis: recurrence after suppressive therapy--can we call for life-long prophylaxis?
    Munusamy V; Nothnagle M; Zaidi N
    Med Health R I; 2008 Sep; 91(9):283-4. PubMed ID: 18834047
    [No Abstract]   [Full Text] [Related]  

  • 20. Continuing the use of the Cockcroft-Gault equation for drug dosing in patients with impaired renal function.
    Spruill WJ; Wade WE; Cobb HH
    Clin Pharmacol Ther; 2009 Nov; 86(5):468-70. PubMed ID: 19844221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.